The World’s First Autonomous Blood Drawing Device

Informazioni relative al progetto

VD-1

ID dell’accordo di sovvenzione: 190176843

DOI

10.3030/190176843

Progetto chiuso

Data della firma CE 14 Luglio 2023

Data di avvio 1 Giugno 2023

Data di completamento 28 Febbraio 2025

Finanziato da

• The European Innovation Council (EIC)

Costo totale

€ 2 975 301,25

Contributo UE

€ 2 082 710,88

Coordinato da

VITESTRO BV
Netherlands

Periodic Reporting for period 2 - VD-1 (The World’s First Autonomous Blood Drawing Device)

Periodo di rendicontazione: 2024-04-01 al 2025-02-28

Sintesi del contesto e degli obiettivi generali del progetto

Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

- We worked on the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,400 patients in 4 European Hospital Laboratory sites.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software.
- We have obtained CE marking and can thereby sell the device within the EU.
- We have placed the first two devices in a commercial setting in the OLVG hospital in Amsterdam

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have signed contracts with 5 different customers for a total of 13 devices
- We have grown the team from 50 to ~100 people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have a total of nine patents filed on all essential parts of the device